1
Appendix 1: Draft Eligibility Criteria
2
Level 1 screening
3
4
1. Does this study include adult patients (aged ≥ 18 years) or children who are undergoing
chemotherapy or surgery?
5
6
7
8
9
10
11
YES____
NO____
2. Is this an experimental, quasi-experimental or cohort study?
YES____
NO____
UNCLEAR____
3. Are patients treated with the following 5-HT3 receptor inhibitors?
YES____
NO____
Generic name
Ondansetron
Dolasetron
Granisetron
Palonosetron
12
13
14
15
16
17
18
19
UNCLEAR____
UNCLEAR____
Trade name(s)
Zofran
Azemet, Anemet
Sancuso, Kytril, Kevatril
Aloxi, Alexi
4. Does the study compare a 5-HT3 receptor inhibitor with another 5-HT3 receptor inhibitor, placebo,
and/or other antiemetic agents?
YES____
NO____
UNCLEAR____

If you answer NO to any of these questions, the citation/study will be excluded. All othercitations
will be included.
1
20
Level 2 screening
21
22
1. Does this study include adult patients (aged ≥ 18 years) or children who are undergoing
chemotherapy or surgery?
23
24
25
26
27
28
29
YES____
NO____
UNCLEAR____
2. Is this an experimental, quasi-experimental or cohort study?
YES____
NO____
UNCLEAR____
3. Are patients treated with the following 5-HT3 receptor inhibitors?
YES____
NO____
UNCLEAR____
Generic name
Trade name(s)
Zofran
Azemet, Anemet
Ondansetron
Dolasetron
Granisetron
Palonosetron
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
Sancuso, Kytril, Kevatril
Aloxi, Alexi
4. Does the study compare a 5-HT3 receptor inhibitor with another 5-HT3 receptor inhibitor, placebo,
and/or other antiemetic agents?
YES____
NO____
UNCLEAR____
5. Does the study report at least one of the following outcomes?
Arrhythmia, sudden cardiac death, QT prolongation, PR prolongation, all-cause mortality, nausea, or
vomiting.
YES____
NO____
UNCLEAR____
 If you answer NO to any of these questions, the citation/study will be excluded. All other full-text
articles will be included.
2
46
Appendix 2: Draft literature search for MEDLINE
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
Ondansetron/ [ Ondansetron ]
ondansetron.mp.
zofran.mp.
SN-307.mp.
SN307.mp.
GR38032F.mp.
GR-38032F.mp.
GR C50775.mp.
99614-02-5.rn. [ CAS Registry ]
bryterol.mp.
cedantron.mp.
ceramos.mp.
emeset.mp.
modifical.mp.
narfoz.mp.
onsia.mp.
sakisozin.mp.
vomceran.mp.
zofrene.mp.
zefron.mp.
zophron.mp.
zophran.mp.
zuplenz.mp.
zophren.mp.
zudan.mp.
Granisetron/ [ Granisetron ]
granisetron$.mp.
kytril.mp.
BRL-43694.mp.
BRL43694.mp.
109889-09-0.rn. [ CAS Registry ]
apf 530.mp.
eutrom.mp.
granicip.mp.
granisol.mp.
kevatril.mp.
sancuso.mp.
taraz.mp.
dolasetron.mp. [ Dolasetron ]
anzemet.mp.
anemet.mp.
zamanon.mp.
MDL 73,147EF.mp.
MDL-73147EF.mp.
3
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
dolasetron.rn. [ CAS Registry ]
palonosetron.mp.
135729-61-2.rn. [ CAS Registry ]
onicit.mp.
aloxi.mp.
2-Qhbiqo.mp.
Serotonin 5-HT3 Receptor Antagonists/
5ht3.mp.
5-HT3.mp.
"5-Hydroxytryptamine-3 receptor antagonist?".mp.
"serotonin type 3 receptor antagonist$".mp.
"5-hydroxytryptamine-3 antagonist$".mp.
or/1-56
chemotherap$.mp. [ chemotherapy ]
chemo-therap$.mp.
Antineoplastic Combined Chemotherapy Protocols/
exp Antineoplastic Agents/
canc$.mp. [ cancer / oncology ]
carcinoma$.mp.
tumo?r$.mp.
neoplasm$.mp.
on?olog$.mp.
surger$.mp. [ surgery ]
surgical$.mp.
su.fs.
exp Surgical Procedures, Operative/
Nausea/ [ nausea and vomiting ]
Vomiting/
nause$.mp.
vomit$.mp.
emesis.mp.
PONV.mp.
"Postoperative Nausea and Vomiting"/
or/58-77
57 and 78
exp Animals/ not (exp Animals/ and Humans/)
79 not 80
4